Our History

What is now Elucid Bioimaging began studies in 2009 with a mission to help reduce the number of heart attacks and strokes by identifying and delivering personalized treatment for the underlying cause of these events. This solution had to be accurate, efficient, and cost effective. After many of supporting studies, Elucid developed vascuCAP® in 2017 to bring our solution to the market and support patient care across the globe.

The Elucid Bioimaging Timeline:

  • 2009
  • 2012-2013
  • 2014-2015
  • 2016-2017
  • 2018
  • Founding and begin animal studies
  • NSF Grant for computer-aided phenotyping of debilitating disease
  • Animal feasibility study with BU published in Medical Physics
  • NIH Direct Phase II Grant Award for Q-CAMP multi-center prospective study
  • Begin filing of blocking patents in objectively-validated phenotyping FORETELL
  • Stroke outcome prediction study with Weill Cornell
  • Human histology studies completed
  • FDA clearance/CE marking of industry’s only specific labelling for tissue characteristics
  • UMD Begins using vascuCAP in CREST Trial
  • Histology validation results published with LSU in Radiology
  • Feasibility studies of data enrichment for deep learning completed
  • QIBA atherosclerosis biomarker elects AJB as Chair
  • PoSTCARD MACE outcome prediction study completed
    Coronary 510(k)
  • Clearance and extended labeling